Eli Lilly and Company, a pharmaceutical company based in Indianapolis, Indiana, revealed it has teamed up with Amazon Pharmacy to help deliver its Zepbound weight loss drug and other medicines straight to customers' homes.
It struck a partnership deal with the online pharmacy subsidiary of Amazon Inc. just four months after obtaining the required regulatory approval to sell its diabetes treatment under a different name and category: weight loss.
Lilly's Weight Loss Treatment
According to CBS News, Eli Lilly's Tirzepatide drug, currently sold as a Mounjaro brand for diabetes, is now on the market under the new name Zepbound. It is also advertised as a weight-loss medication administered using an injection pen.
The company reportedly started selling Zepbound earlier this year. The drugs are directly sold to patients. Patients consult with doctors and obtain prescriptions from digital pharmacies, and the drugs are delivered to them.
Amazon Pharmacy Added as Home Delivery Option
Its partnership with Amazon's pharmacy unit allows patients and customers to obtain their medications quickly. In addition to Amazon Pharmacy, Eli Lilly delivers drugs to its customers via Truepill.
"Lilly has selected Amazon Pharmacy as a dispensing pharmacy option, allowing patients to receive fast, free delivery of medications and 24/7 access to clinical pharmacists," Dr. Vin Gupta, Amazon Pharmacy's chief medical officer, said in a press release. "To help patients being treated for diabetes, obesity, and migraine, Amazon Pharmacy is now offering home delivery of select medications through LillyDirect."
Dr. Gupta added, "Lilly has selected Amazon Pharmacy to serve as a third-party dispensing provider for LillyDirect Pharmacy Solutions, delivering prescribed Lilly medications directly to a patient's home."
Photo by: James Yarema/Unsplash


Australia Moves Forward With Teen Social Media Ban as Platforms Begin Lockouts
Tesla Expands Affordable Model 3 Lineup in Europe to Boost EV Demand
Anthropic Reportedly Taps Wilson Sonsini as It Prepares for a Potential 2026 IPO
Airbus Faces Pressure After November Deliveries Dip Amid Industrial Setback
Sam Altman Reportedly Explored Funding for Rocket Venture in Potential Challenge to SpaceX
EU Prepares Antitrust Probe Into Meta’s AI Integration on WhatsApp
IKEA Launches First New Zealand Store, Marking Expansion Into Its 64th Global Market
Netflix Nearing Major Deal to Acquire Warner Bros Discovery Assets
Wikipedia Pushes for AI Licensing Deals as Jimmy Wales Calls for Fair Compensation
GM Issues Recall for 2026 Chevrolet Silverado Trucks Over Missing Owner Manuals
Magnum Audit Flags Governance Issues at Ben & Jerry’s Foundation Ahead of Spin-Off
Microchip Technology Boosts Q3 Outlook on Strong Bookings Momentum
Michael Dell Pledges $6.25 Billion to Boost Children’s Investment Accounts Under Trump Initiative
Tesla Faces 19% Drop in UK Registrations as Competition Intensifies
OpenAI Moves to Acquire Neptune as It Expands AI Training Capabilities
ExxonMobil to Shut Older Singapore Steam Cracker Amid Global Petrochemical Downturn
Visa to Move European Headquarters to London’s Canary Wharf 



